Detalles de la búsqueda
1.
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Gut
; 72(2): 295-305, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35902214
2.
Fecal Calprotectin in Gastrointestinal Disease.
Clin Chem
; 69(7): 699-710, 2023 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37228058
3.
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Gut
; 70(10): 1884-1893, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33903149
4.
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Gut
; 70(5): 865-875, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33753421
5.
Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Gastroenterology
; 149(6): 1564-1574.e3, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26170138
6.
Regulation of phosphoinositide 3-kinase expression in health and disease.
Trends Biochem Sci
; 34(3): 115-27, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19299143
7.
Nutritional care pathways in cancer patients with malignant bowel obstruction: A retrospective multi-centre study.
Clin Nutr ESPEN
; 59: 118-125, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38220364
8.
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Lancet Gastroenterol Hepatol
; 9(5): 415-427, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402895
9.
Understanding and managing psychological disorders in patients with inflammatory bowel disease: a practical guide.
Frontline Gastroenterol
; 14(1): 78-86, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36561780
10.
Mucosal Immunity to Gut Fungi in Health and Inflammatory Bowel Disease.
J Fungi (Basel)
; 9(11)2023 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37998910
11.
BSG 2024 IBD guidelines protocol (standard operating procedures).
BMJ Open Gastroenterol
; 10(1)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36764690
12.
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Lancet Gastroenterol Hepatol
; 8(2): 145-156, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36481043
13.
Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
J Crohns Colitis
; 2023 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37941436
14.
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
EClinicalMedicine
; 64: 102249, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37842172
15.
The dietary practices and beliefs of British South Asian people living with inflammatory bowel disease: a multicenter study from the United Kingdom.
Intest Res
; 20(1): 53-63, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33396977
16.
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study.
Frontline Gastroenterol
; 13(6): 517-523, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36250172
17.
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
J Crohns Colitis
; 16(3): 389-397, 2022 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34473254
18.
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab.
Frontline Gastroenterol
; 13(5): 392-401, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36051959
19.
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
Lancet Gastroenterol Hepatol
; 7(4): 342-352, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123676
20.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Nat Commun
; 13(1): 1379, 2022 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35296643